Posted inComunicati
DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast Cancer
COMUNICATO STAMPA - CONTENUTO PROMOZIONALE SHANGHAI, April 9, 2026 /PRNewswire/ -- DualityBio ("DualityBio" or the…









